
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Psycheceutical
Deal Size : $10.5 million
Deal Type : Acquisition
Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences
Details : Vici is an end-to-end pharmaceutical research and development company specializing in taking projects from pre-clinical research through the Phase 2 stage of FDA approval.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $10.5 million
August 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Psycheceutical
Deal Size : $10.5 million
Deal Type : Acquisition
